There are 2789 resources available
1364TiP - Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy
Presenter: Byoung Chul Cho
Session: ePoster Display
1450P - Criteria for referral of cancer patients to palliative care in Indian hospitals: A modified Delphi consensus
Presenter: Gaurav Chanana
Session: ePoster Display
Resources:
Abstract
1451P - An onco-palliative expertise unit in a French comprehensive cancer center: Experience at 2 years
Presenter: Perrine RENARD
Session: ePoster Display
1452P - Use of the Pallia 10 score in patients enrolled in phase I trials at Gustave Roussy Cancer Center
Presenter: Kaissa Ouali
Session: ePoster Display
1226P - Efficacy and safety of Anti-EGFR TKIs combined with bevacizumab or ramucirumab in the first-line treatment of non-small cell lung cancer: Meta-analysis of randomized controlled trials
Presenter: Yakup Ergün
Session: ePoster Display
1229P - Co-mutation of DNA damage repair (DDR) genes influence the efficiency of EGFR-TKIs in NSCLC patients harboring EGFR activating mutations
Presenter: Linlin Zhang
Session: ePoster Display
1230P - Elderly patients treated with afatinib in clinical practice: Final results of the GIDEON study in EGFR mutated NSCLC in Germany
Presenter: Wolfgang M Brueckl
Session: ePoster Display
1231P - Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy
Presenter: James Chih-Hsin Yang
Session: ePoster Display